Survival after combined modality therapy for pancreatic cancer

Howard W. Bruckner, Shalom Kalnicki, Jack Dalton, Harry Snady, Gary K. Schwartz, Margaret R. Chesser, Deborah Lehrer, John Mandeli, Noam Harpaz, Cynthia Janus

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unrespectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalJournal of Clinical Gastroenterology
Volume16
Issue number3
StatePublished - 1993
Externally publishedYes

Fingerprint

Combined Modality Therapy
Pancreatic Neoplasms
Survival
Streptozocin
Fluorouracil
Cisplatin
Neoplasms
Radiotherapy
Therapeutics
Survival Rate
Retrospective Studies
Drug Therapy

Keywords

  • 5-Fluorouracil
  • Chemotherapy
  • Cisplatin
  • Combined modality therapy
  • Pancreatic cancer
  • Radiotherapy
  • Streptozotocin

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Bruckner, H. W., Kalnicki, S., Dalton, J., Snady, H., Schwartz, G. K., Chesser, M. R., ... Janus, C. (1993). Survival after combined modality therapy for pancreatic cancer. Journal of Clinical Gastroenterology, 16(3), 199-203.

Survival after combined modality therapy for pancreatic cancer. / Bruckner, Howard W.; Kalnicki, Shalom; Dalton, Jack; Snady, Harry; Schwartz, Gary K.; Chesser, Margaret R.; Lehrer, Deborah; Mandeli, John; Harpaz, Noam; Janus, Cynthia.

In: Journal of Clinical Gastroenterology, Vol. 16, No. 3, 1993, p. 199-203.

Research output: Contribution to journalArticle

Bruckner, HW, Kalnicki, S, Dalton, J, Snady, H, Schwartz, GK, Chesser, MR, Lehrer, D, Mandeli, J, Harpaz, N & Janus, C 1993, 'Survival after combined modality therapy for pancreatic cancer', Journal of Clinical Gastroenterology, vol. 16, no. 3, pp. 199-203.
Bruckner HW, Kalnicki S, Dalton J, Snady H, Schwartz GK, Chesser MR et al. Survival after combined modality therapy for pancreatic cancer. Journal of Clinical Gastroenterology. 1993;16(3):199-203.
Bruckner, Howard W. ; Kalnicki, Shalom ; Dalton, Jack ; Snady, Harry ; Schwartz, Gary K. ; Chesser, Margaret R. ; Lehrer, Deborah ; Mandeli, John ; Harpaz, Noam ; Janus, Cynthia. / Survival after combined modality therapy for pancreatic cancer. In: Journal of Clinical Gastroenterology. 1993 ; Vol. 16, No. 3. pp. 199-203.
@article{926cdf5ffb1447d9af1a739c7b843a4f,
title = "Survival after combined modality therapy for pancreatic cancer",
abstract = "Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unrespectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.",
keywords = "5-Fluorouracil, Chemotherapy, Cisplatin, Combined modality therapy, Pancreatic cancer, Radiotherapy, Streptozotocin",
author = "Bruckner, {Howard W.} and Shalom Kalnicki and Jack Dalton and Harry Snady and Schwartz, {Gary K.} and Chesser, {Margaret R.} and Deborah Lehrer and John Mandeli and Noam Harpaz and Cynthia Janus",
year = "1993",
language = "English (US)",
volume = "16",
pages = "199--203",
journal = "Journal of Clinical Gastroenterology",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Survival after combined modality therapy for pancreatic cancer

AU - Bruckner, Howard W.

AU - Kalnicki, Shalom

AU - Dalton, Jack

AU - Snady, Harry

AU - Schwartz, Gary K.

AU - Chesser, Margaret R.

AU - Lehrer, Deborah

AU - Mandeli, John

AU - Harpaz, Noam

AU - Janus, Cynthia

PY - 1993

Y1 - 1993

N2 - Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unrespectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.

AB - Twenty consecutive patients with unresectable, locally advanced pancreatic cancer were treated with split courses of radiotherapy (RT) and simultaneous multidrug chemotherapy consisting of 5 fluorouracil, continuous infusion, streptozotocin, and cisplatin. A separate, retrospective study identified a group of 28 contemporary patients with less advanced pancreatic cancers, all of which were successfully resected. The survival rate of the two groups were similar over the first 2 years, although it initially favored the unresectable group. This pattern of survival among patients treated with combined modality therapy provides a basis for new studies. At the two clinical extremes, these include treatment of unrespectable tumors previously considered ineligible for this treatment and initial treatment before resection of stage I tumors.

KW - 5-Fluorouracil

KW - Chemotherapy

KW - Cisplatin

KW - Combined modality therapy

KW - Pancreatic cancer

KW - Radiotherapy

KW - Streptozotocin

UR - http://www.scopus.com/inward/record.url?scp=0027468492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027468492&partnerID=8YFLogxK

M3 - Article

C2 - 8505490

AN - SCOPUS:0027468492

VL - 16

SP - 199

EP - 203

JO - Journal of Clinical Gastroenterology

JF - Journal of Clinical Gastroenterology

SN - 0192-0790

IS - 3

ER -